Robert Peach Buys 827,268 Shares of Amplia Therapeutics Limited (ASX:ATX) Stock

Amplia Therapeutics Limited (ASX:ATX) insider Robert Peach bought 827,268 shares of the stock in a transaction dated Wednesday, June 19th. The shares were bought at an average cost of A$0.06 ($0.04) per share, with a total value of A$45,499.74 ($30,333.16).

Amplia Therapeutics Price Performance

The company has a quick ratio of 5.05, a current ratio of 3.43 and a debt-to-equity ratio of 15.18.

About Amplia Therapeutics

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney.